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ABSTRACT 
 
Humans with biliary cirrhosis are highly susceptible to acute pulmonary dysfunction and suffer 
from hepato-pulmonary syndrome. The mechanisms of this enhanced susceptibility remain 
unknown. It is well established that pulmonary intravascular macrophages (PIMs) are present 
in cattle, horses, goat and sheep and increase susceptibility for lung inflammation. Species such 
as rat and mouse also recruit PIMs especially in a bile duct ligation model of biliary cirrhosis. 
The contributions of recruited PIMs to lung inflammation associated with liver dysfunction 
remain unknown. Therefore, I characterized a bile duct ligation (BDL) model in rats to study 
role of recruited PIMs in lung inflammation. First, Sprague Dawley rats were subjected to BDL 
(N=6) or sham surgeries (N=3) and were euthanized at 4 weeks post-surgery. Five rats were 
used as the controls. Lung tissues were collected and processed for histology, 
immunohistology, immuno-electron microscopy, enzyme-linked immunosorbant assay 
(ELISA) and reverse transcriptase-polymerase chain reaction (RT-PCR). Light microscopy 
demonstrated normal lung morphology in sham-operated and control rats but showed septal 
recruitment of mononuclear cells, which were positive for anti-rat monocytes/macrophage 
antibody ED-1, in BDL rats. (p=0.002). Immuno-electron microscopy confirmed localization 
of ED-1 in PIMs. BDL rats showed increased lung expression of monocyte chemoattractant 
protein-1 (MCP-1) protein and mRNA compared to the controls (p=0.017) but not of IL-1β, 
TNF-α, TGF-β and IL-10. Then, I treated BDL rats (N=5) with gadolinium chloride (GC; 10 
mg/Kg body weight intravenous) and found reduced numbers of PIMs (p=0.061) at 48 hours 
post-treatment along with increased expression of TGF-β and IL-10.  
 
I challenged control rats (N=5) and BDL rats (N=6) with Escherichia coli lipopolysaccharide 
(E. coli LPS; 0.1 mg/Kg body weight intravenous). All the BDL rats died within 3 hours of 
LPS challenge (100% mortality) while the normal LPS-treated rats were euthanized at 6 hours 
post-treatment. Histology and ED-1 staining showed dramatic increase in the number of septal 
monocytes/macrophages in BDL+LPS rats compared to normal LPS-treated rats (p=0.000). 
Staining of lung sections with an LPS antibody localized the LPS in lungs. RT-PCR analyses 
showed no differences in IL-1β transcript levels between LPS challenged BDL rats and LPS 
challenged control rats (p=0.746) but ELISA showed increase in IL-1β concentration in LPS 
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challenged BDL rats compared to LPS challenged control rats (p=0.000). TNF-α mRNA 
(p=0.062) and protein (p=0.000) was increased in BDL+LPS rats compared to the 
control+LPS rats. Immuno-electron microscopy showed IL-1β and TNF-α in PIMs. BDL rats 
challenged with LPS showed increased expression of IL-10 mRNA and protein (p=0.000 & 
0.002 respectively) in lungs compared to LPS challenged control rats. TGF-β mRNA did not 
change (p=0.128) but lower protein concentrations (p=0.000) were observed in LPS-treated 
control rats compared to BDL+LPS.  
 
To further address the role of PIMs, I treated rats with GC at 6 hours or 48 hours (N=5 each) 
before LPS challenge. The mortality in the 6 hour group was 20% while all the rats in 48 hour 
group survived till 6 hours. Histology and ED-1 staining showed decrease in the number of 
intravascular cells in these groups compared to LPS treated BDL rats (p=0.039 for 6 hour 
group; p= 0.002 for 48 hour group). There were no differences in IL-1β mRNA in both 6 hour 
and 48 hour groups compared to the LPS challenged BDL rats (p=0.712 & 0.509 respectively). 
ELISA showed no decrease in IL-1β concentration in 6 hour GC-treated group but a decrease 
was noticed at 48 hours compared to LPS challenged BDL rats (p=0.455 & 0.008 
respectively). TNF-α mRNA levels were not different between LPS-challenged GC-treated 
BDL rats and LPS-challenged BDL rats (p=0.499 & 0.297 for 6 hour & 48 hour GC groups 
respectively). But TNF-α concentration in 48 hour GC group (p=0.001) but not in 6 hour GC 
group (p=0.572) was lower in comparison to BDL+LPS group. IL-10 mRNA was decreased in 
both 6 hour and 48 hour GC groups (p=0.038 & 0.000 respectively) compared to LPS 
challenged BDL rats. ELISA showed decrease in IL-10 concentration in 48 hour GC group 
(p=0.030) but not in 6 hour GC group (p=0.420). TGF-β mRNA expression was decreased in 
48 hour GC group (p=0.000) but not in 6 hour GC group (p=0.182). But GC treatment did not 
affect TGF-β concentrations.  
 
The data from these experiments characterize a BDL model to study PIM biology, show PIMs’ 
pro-inflammatory potential and their possible role as a therapeutic target in lung inflammation.  
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1. INTRODUCTION   
 
1.1. Inflammation:  
Inflammation is the body's reaction to invasion by an infectious agent, antigen challenge 
or physical, chemical or traumatic damage. It is a complex reaction involving a number 
of cellular and molecular components with accompanying changes in the physiological 
systems. During inflammation, blood supply to the inflamed tissue increases and the 
inflamed tissue appears to contain greater number of blood vessels. Capillary 
permeability increases, which is partly caused by retraction of endothelial cells (Thickett 
et al., 2001). This permits large molecules to escape from the capillaries and thus allow 
the soluble mediators of inflammation to reach the site of inflammation. There is also 
increased leukocyte migration out of the capillaries into the surrounding tissues. In the 
earliest stages of inflammation, neutrophils are particularly prevalent, but later monocytes 
and lymphocytes migrate towards the site of infection (Kaplanski et al., 2003), (Larsen 
and Holt, 2000). The development of inflammatory reaction is controlled by cytokines 
(Dinarello, 1997), by products of the plasma enzyme system (Barrington et al., 2001), by 
lipid mediators (Robinson1987), and by vasoactive mediators released from the mast 
cells (Wasserman, 1987), basophils (Holgate, 2000) and platelets (Weyrich et al., 2003).  
Because inflammation is a complex interplay involving a variety of cells and molecules, 
the outcomes are usually determined by the balance between pro- and anti-inflammatory 
forces. For example excessive accumulation of activated neutrophils usually results in 
profound tissue damage and mortality. However, the inflammation process has inbuilt 
checks to tightly regulate the neutrophil recruitment and expression of various mediators. 
Therefore, the inflammation can at best be described as an essential reaction designed to 
protect the host.  
 
1.2. Lung inflammation: 
The epithelial surface area of the lung is large compared to epithelial surface area of other 
organs in the body. Lung epithelium is continuously exposed to the external environment 
and is always in direct contact with different types of injurious agents. Because of the 
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circulation of blood from whole of the body through the lungs, lungs are also 
continuously exposed to blood-borne bacteria, viruses or endotoxins. This makes lungs 
highly vulnerable to both air-borne and blood-borne infectious agents. Although there are 
many causes for lung inflammation, bacteria and their endotoxins play very important 
role in inducing acute lung inflammation. Endotoxemia is defined as the presence of 
endotoxins in the blood in sufficient amounts to cause disease. Endotoxin-induced 
systemic activation of the immune system includes cytokine production, complement 
activation, platelet aggregation and activation of immune cells. Endotoxin activates 
immune cells such as macrophages through a pathway which makes use of a receptor 
known as TLR-4 (Nomura et al., 2000). Interaction of TLR-4 on the cell surface with two 
other surface proteins, CD14 and MD2, leads to the recruitment of adaptor proteins 
(Myd88, IRAK, and TRAF-6) that ultimately induces activation of transcription factor 
complex NF-kB (Aderem and Ulevitch, 2000).  
 
Translocation of NF-kB into cell nucleus promotes expression of inflammatory mediators 
such as TNF-α, IL-1β, IL-6 and IL-8 (Sweet and Hume, 1996). Pro-inflammatory 
mediators such as TNF-α and IL-1β cause up-regulation of adhesion molecules on the 
pulmonary vascular endothelium (E-selectins, ICAM-1) as well as alveolar epithelium 
(ICAM-1) (Strieter et al., 2002). Vascular adhesion molecules enhance adhesiveness of 
polymorphonuclear cells such as neutrophils and facilitate their transmigration into the 
interstitium and distal airways (Bevilacqua, 1993). Alveolar epithelial ICAM-1 enhances 
adhesiveness of alveolar macrophages to the epithelial cells, resulting in intensified 
production of cytokines and chemokines (Beck-Schimmer et al., 2002). 
 
1.3. Pro-inflammatory cytokines:  
 
1.3.1. TNF-α and IL-1β 
TNF-α and IL-1β are two of the most important "acute response" cytokines induced most 
notably via TLR-4 signaling pathway (Strieter et al., 2002). TNF-α is a hormone like 
polypeptide that possesses a wide range of immunologic, metabolic and inflammatory 
activities. TNF-α is mainly produced by monocytes and macrophages in bacterial 
 3
infections or endotoxemia (Beutler and Kruys, 1995). TNF-α is initially expressed as a 
233-amino-acid membrane-anchored precursor, which is proteolytically processed to 
yield the mature, 157-amino-acid cytokine (Gearing et al., 1994). TNF-α is released from 
a cell membrane-anchored precursor by proteolytic cleavage by metalloproteinase 
enzyme (Gearing et al., 1995). Mature TNF-α is a trimeric molecule, each subunit of 
which consists of an antiparallel beta-sandwich (Jones et al., 1989). 
 IL-1β is a protein synthesized by a variety of cells, but primarily by monocyte-
macrophages, in response to various stimuli such as bacteria, endotoxins and other 
cytokines (Cybulsky et al., 1987). IL-1β also exists in the form of precursor protein (pro-
IL-1β), which is then cleaved by the enzyme into the mature form (Boraschi et al., 1996). 
TNF-α and IL-1β are produced by activated macrophages in response to a variety of 
stimuli such as endotoxin. Macrophages recognize endotoxin through receptor known as 
TLR-4 present on their surface (Nomura et al., 2000). TLR-4 through interaction with 
other proteins activates transcriptional factor complex NF-kB within the activated 
macrophage and leads to the expression of genes for TNF-α and IL-1β (Aderem and 
Ulevitch, 2000). TNF-α and IL-1β upregulates expression of adhesion molecules on 
pulmonary vascular endothelium and alveolar epithelium to promote recruitment of 
neutrophils into inflamed lungs (Strieter et al., 2002) (Bevilacqua1993).  
  
1.3.2. MCP-1  
Monocyte chemotactic protein-1 (MCP-1) is derived from mononuclear cells and other 
cell sources including macrophages. It is a potent chemoattractant for monocytes and 
macrophages. There are two isoforms of MCP-1 (13kD & 9kD), which can be 
distinguished by lectin binding (Jiang et al., 1991). MCP-1 plays a key role in monocyte 
recruitment by both integrin activation and by promoting migration of monocytes to the 
blood vessels (Ashida et al., 2001). Therefore, MCP-1 helps in recruitment of leukocytes 
to lung (Warren et al., 1993). MCP-1 gene expression is regulated by oxidation-reduction 
sensitive mechanism and reactive oxygen species such as superoxide anion, hydrogen 
peroxide, hydroxyl nitrate and peroxynitrite and TNF-α (Chen et al., 2004). MCP-1 
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expression in the lungs increases in response to silica, smoke and endotoxins.  MCP-1 has 
also a crucial role in the resolution and repair processes of acute bacterial pneumonia by 
enhancing the removal of dying neutrophils and hepatic growth factor (HGF) production 
by alveolar macrophages (Amano et al., 2004). MCP-1 concentrations increase early in 
the course of multiple organ failure and this suggest that this chemokine is important in 
the early inflammatory changes that lead to multiple organ failure later in the course of 
this illness (Thomas et al., 2005). MCP-1 gene expression increases in bleomycin 
induced lung fibrosis in rats and infiltrating eosinophils represent the major cellular 
source of increased MCP-1 expression (Zhang et al., 1994). Therefore, MCP-1 appears to 
be a critical regulator of acute inflammation including that in the lungs. 
 
1.4. Anti-inflammatory cytokines: 
The anti-inflammatory cytokines constitute a group of immunoregulatory molecules that 
control the response of pro-inflammatory cytokines. The anti-inflammatory cytokines 
along with other specific cytokine inhibitors and soluble cytokine receptors helps to limit 
the potentially injurious effects of sustained or excess inflammatory reactions (Opal and 
DePalo, 2000). There exists a fine balance between anti-inflammatory cytokines and pro-
inflammatory cytokines. 
 
1.4.1. IL-10 
IL-10 is primarily synthesized by monocytes, CD4+ Th2 cells and B cells. It circulates as 
a homodimer consisting of two tightly packed 160 amino acid proteins (Howard et al., 
1992). In addition to its Th2 inhibitory activity, it is also a potent deactivator of 
monocyte/macrophage pro-inflammatory cytokine production (Brandtzaeg et al., 1996). 
IL-10 inhibits cell surface expression of major histocompatibility complex class-II 
molecules and the LPS recognition and signaling molecule CD14 (Opal et al., 1998). It 
inhibits nuclear translocation of NF-kB after LPS stimulation and promotes degradation 
of mRNA for the pro-inflammatory cytokines (Clarke et al., 1998). IL-10 suppresses 
cytokine production by neutrophils and natural killer cells. IL-10 also attenuates surface 
expression of TNF receptors and also promotes the shedding of TNF receptors into the 
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systemic circulation (Dickensheets et al., 1997). Addition of IL-10 to the cultures of 
monocytes, which were activated by IFN-γ, LPS or combination of both resulted in the 
inhibition of production of IL-1α, IL-1β, IL-6, IL-8, TNF-α, GM-CSF and G-CSF at the 
transcriptional level (de Waal et al., 1991). Also activation of monocytes by LPS in the 
presence of neutralizing anti-IL-10 monoclonal antibodies resulted in the production of 
higher amounts of cytokines as compared to LPS treatment alone (de Waal et al., 1991). 
In a similar study in mice, where endotoxemia induced by the injection of LPS resulted in 
the rapid release of IL-10 and neutralization of endogenously produced IL-10 by 
administration of anti-IL-10 monoclonal antibody prior to LPS challenge resulted in a 
marked increase in the serum levels of TNF-α and IFN- γ (Marchant et al., 1994). Low 
concentrations of IL-10 in patients with early adult respiratory distress syndrome (ARDS) 
indicates poor prognosis and accounts for increased mortality rate (Donnelly et al., 1996). 
Similarly, administration of IL-10 in humans after LPS challenge resulted in fewer 
systemic symptoms, neutrophil responses and chemokine production (MIP-1, MCP-1) 
than placebo-treated control subjects (Olszyna et al., 2000). These data demonstrate 
innate anti-inflammatory actions of IL-10. 
 
1.4.2. TGF-β 
TGF-β belongs to a superfamily of dimeric proteins that share a similar structure. It is 
synthesized as an inactive precursor and requires activation to exert its effects. The active 
molecule is a 25-kd homodimer of two 12.5-kd disulphide-linked monomers. There are 
three isoforms of TGF-β designated as TGF-β1, TGF-β2 and TGF-β3 (Roberts, 1998). 
TGF-β is produced by lymphocytes, macrophages and dendritic cells and its expression 
control the differentiation, proliferation and state of activation of these immune cells 
(Letterio and Roberts, 1998). TGF-β is an important regulator of cell proliferation, 
differentiation and formulation of the extracellular matrix. Release and activation of 
TGF-β stimulates the production of various extracellular matrix proteins and thus 
contribute to tissue repair (Branton and Kopp, 1999).  
 
TGF-β modulates the expression of adhesion molecules which in turn provides a 
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chemotactic gradient for leukocytes and other inflammatory cells and TGF-β then 
inhibits them once they become activated (Letterio and Roberts, 1998). TGF-β stimulates 
several processes that are important for tissue repair following lung injury which 
includes, reducing production of pro-inflammatory cytokines from macrophages, 
promoting recruitment of fibroblasts, differentiating myofibroblasts and stimulating the 
production of extra-cellular matrix proteins (Lasky and Brody, 2000). TGF-β signaling 
and regulation are mediated by a family of Smad proteins.  TGF-β induces 
phosphorylation of Smad proteins, which then translocate to the nucleus and regulate 
transcription of target genes (Massague, 1998). Over-expression of TGF-β enhances 
synthesis and deposition of extra-cellular matrix components including collagen and also 
alters the balance of matrix metalloproteinase and their inhibitors. This signals a very 
important role for TGF-β in the pathogenesis of pulmonary fibrosis (Broekelmann et al., 
1991). IL-7 inhibits TGF-β signaling by up-regulating Smad7 protein, which is a major 
inhibitor of Smad family and thus reduces TGF-β mediated collagen synthesis which has 
a beneficial effect on pulmonary fibrosis (Zhang et al., 2004). IL-13 released from 
infiltrating cells following injury to airway epithelium and increased secretion of TNF-α 
in early stages of inflammation stimulates production of TGF-β (Strieter, 2002; Hira et 
al., 2003). Integrin αvβ6 is also associated with activation of latent TGF-β (Strieter, 
2002). TGF-β1 is the most abundant isomer and plays a central role in remodeling and 
repair of injured lung tissue (Zhang et al., 1995). Myofibroblasts, fibroblasts and 
eosinophils are the major sources of TGF-β1 in bleomycin-induced lung fibrosis (Zhang 
et al., 1995). Activated fibroblasts contain TGF-β1, which in turn express increased 
levels of fibronectin and procollagen and increased deposition of extra-cellular matrix 
(Broekelmann et al., 1991). In addition to promoting differentiation in myofibroblasts, 
TGF-β1 also protects myofibroblasts against apoptotic stimuli (Phan, 2002). Therefore, 
TGF-β1 is crucial for repair associated with inflammation. 
 
1.5. Pulmonary Intravascular Macrophages: 
Pulmonary intravascular macrophages (PIMs) are present in the lumen of pulmonary 
capillaries and are tightly adhered to their endothelium (Warner, 1996). PIMs are large 
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cells (10-80 µm diameter) with an indented nucleus, phagolysosomes, pseudopodia and 
adhesive structure holding them firmly to the endothelium (Warner, 1996). PIMs develop 
from circulating monocytes sequestered in the pulmonary capillaries (Staub, 1994). PIMs 
are normally present in certain species such as ruminants, horses, pigs and cat (Atwal et 
al., 1992) (Singh et al., 1994) (Staub, 1994). In these species, PIMs play very important 
role in the phagocytosis of bacteria, endotoxin or foreign particles. There is evidence that 
blood borne bacteria and endotoxins are very efficiently removed by pulmonary 
intravascular macrophages in these species (Warner et al., 1987) (Singh and Atwal,1997).  
Intravenous injection of radio-labeled gold colloid and magnetic iron oxide particles in 
sheep resulted in predominant uptake by pulmonary intravascular macrophages (Warner 
et al., 1986). PIMs participate in the clearance of effete erythrocytes, neutrophils, fibrin 
and cellular debris (Winkler, 1988). PIMs produce various inflammatory mediators to 
initiate or modulate lung inflammation (Watson et al., 1994). PIMs also show some 
immune activity by playing important role in antigen presentation i.e., presenting antigen 
to T-lymphocytes (Chitko-McKown et al., 1991). Species that normally contain PIMs are 
highly susceptible to lung inflammation (Longworth, 1997).  
 
Neonatal lambs that normally have few PIM at birth were less responsive to the injection 
of liposomes or Monastral blue particles as compared to 2 week old lambs that normally 
have large number of PIMs and showed pulmonary responses to liposomes or Monastral 
blue (Longworth et al., 1992). Inhibition of PIMs by administration of detergent resulted 
in less pulmonary responses to E. coli endotoxin in horses (Longworth et al., 1996). PIM 
depletion in horses by intravenous administration of gadolinium chloride substantially 
reduced recruitment of inflammatory cells in alveolar septa following LPS administration 
(Parbhakar et al., 2005). Similarly, removal of PIMs before inoculation of Mannheima 
hemolytica in calves caused significant reduction in the number of IL-8 and TNF-α  
positive cells and thus inhibition of acute lung inflammation (Singh et al., 2004).  Pro-
inflammatory nature of PIMs in endotoxin induced lung injury in sheep was also shown 
by depleting PIMs which resulted in decreased pulmonary hypertension and edema (Sone 
et al., 1999). PIMs secrete TNF-α, IL-1β, leukotriene-B, thromboxane and arachidonic 
acid metabolites which in turn promote inflammatory response (Chitko-McKown et al., 
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1991). Recent evidence from in vivo studies showed presence of TNF-α and IL-1β in 
cattle and horse PIMs  (Singh et al., 2004) (Parbhakar et al., 2005). These studies have 
established a critical proinflammatory role for PIMs in acute lung inflammation in 
domestic animal species. 
  
1.6. Recruitment of pulmonary intravascular macrophages 
Species that do not harbor PIMs include humans, dogs, rats and mice (Staub, 1994). 
These species can tolerate large doses of endotoxin without showing significant 
pulmonary vascular responses and edema as compared to species that normally contain 
PIMs (Chang et al., 1987), (Berczi et al., 1966). These species are also less susceptible 
to acute lung inflammation as compared to ruminants (Staub, 1994), (Longworth, 1997). 
However, these species can recruit PIMs under certain experimental conditions such as 
liver injury induced by chronic bile duct ligation, infusion of endotoxin and inhalation of 
100% oxygen (Chang and Ohara, 1994), (Singh et al., 1998). Bile duct ligation in rats 
resulted in the appearance of a large number of mononuclear phagocytes 
morphologically similar to intravascular macrophages (Chang and Ohara, 1994). It was 
further supported by the retention of significant quantities of fluorescent microspheres in 
bile duct ligated rats. Exact mechanism of PIM recruitment in bile duct ligated rats is not 
known, however, it is believed that disruption of liver mononuclear phagocyte system in 
liver injury induced by bile duct ligation causes appearance of intravascular 
macrophages in the lung as a compensatory mechanism. Single intraperitoneal injection 
of E. coli bacteria in rats resulted in the appearance of PIMs with in 48 hours followed 
by their disappearance at 96 hours (Singh et al., 1998). There is also evidence of 
increase in the numbers of intravascular macrophages in the lungs of baboons exposed 
to 100% oxygen.  Recently, PIM recruitment has been reported following exposure to 
the pig barn air and recruited PIMs increased sensitivity to E. coli LPS-induced 
inflammatory response (L. Gamage, MSc thesis). Recruitment of PIMs in rats resulted in 
increased sensitivity to endotoxin (Chang and Ohara, 1994). These studies show that 
under certain physiological stresses, PIMs are recruited in species that normally do not 
possess these cells. However, there is a lack of understanding of recruited PIMs’ 
contributions to lung physiology.   
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1.7. Hepatopulmonary Syndrome 
Hepatopulmonary syndrome (HPS) is characterized by intrapulmonary vascular dilatation 
and increased alveolar to arterial oxygen tension difference which leads to systemic and 
pulmonary vascular abnormalities in humans with advanced liver cirrhosis (Herve et al., 
1998). Rats with cirrhosis induced by bile duct ligation also develop HPS with 
intrapulmonary vascular dilatation and an increased alveolar to arterial oxygen difference 
(Nunes et al., 2001). It is mainly related to excessive production of nitric oxide which in 
turn  depends primarily on increased expression and activity of iNOS within PIMs in 
cirrhotic rats (Nunes et al., 2001). TNF-α is considered to be a potent iNOS activator in 
macrophages, levels of which increases in the blood of cirrhotic rats (Gross et al., 1991).  
Inhibition of TNF-α in cirrhotic rats prevented development of hyperdynamic circulatory 
state and thus HPS mainly by decreasing the vascular overproduction of nitric oxide 
(Sztrymf et al., 2004). Cirrhotic animals showed overgrowth of bacteria in the intestine, 
impairment of the host defense and disruption of mucosal barrier resulting in  vascular 
translocation of bacteria (Wiest et al., 1999). Translocation of bacteria from gut to 
pulmonary circulation is believed to activate intravascular macrophages which contribute 
excessive amounts of nitric oxide (Panos and Baker, 1996). The role of recruited PIMs in 
nitric oxide production is further strengthened by the data that  prevention of 
translocation of bacteria decreases production of nitric oxide from intravascular 
macrophages and thereby reduced the severity of HPS (Rabiller et al., 2002). Therefore, 
PIMs may be an important regulator of development of HPS in rats with end stage liver 
disease and inhibition of their activity may have beneficial effect. 
 
1.8. Bile duct ligation model 
Although rats and humans normally do not contain PIMs, they can recruit PIMs under 
certain conditions such as intra-peritoneal injection of bacteria (Singh et al., 2004), 
(Singh et al., 1998) or induction of biliary cirrhosis by performing bile duct ligation 
(Chang and Ohara, 1994). Intra-peritoneal injection of E. coli resulted in the recruitment 
of large number of activated mononuclear phagocytes, resembling PIMs, in the lung 
microvasculature within 48 hours of treatment with bacteria (Singh et al., 1998). These 
mononuclear phagocytes were transient because they disappeared by 4 - 7 days after 
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treatment with bacteria. On the other hand, biliary cirrhosis induced by bile duct ligation 
resulted in the appearance of PIMs, resembling PIMs of domestic animal species, within 
1 week after bile duct ligation and progressively increased by 2 weeks and 4 weeks 
(Chang and Ohara, 1994). The recruited PIMs were closely adhered to the capillary 
endothelium. These data show that bile duct ligation induces permanent recruitment of 
PIMs compared to the transient accumulation observed following a single intraperitoneal 
injection of bacteria. Rats with ligated bile ducts may be a reliable model to study PIMs’ 
roles in pulmonary diseases in cattle and horses in addition to their recent use as a model 
for HPS.  
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2. HYPOTHESES: 
a. Bile duct ligation induces recruitment of PIMs. 
b. Recruited PIMs increase sensitivity to acute lung inflammation. 
c. Depletion of PIMs protects against the severity of acute lung inflammation 
 
3. OBJECTIVES: 
a. To investigate recruitment of PIMs following bile duct ligation. 
b. To study functions of recruited PIMs in acute lung inflammation. 
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4. RATIONALE:  
Lung inflammatory diseases continue to be a major cause of mortality and morbidity in 
humans as well as domestic animals. Lung inflammation could be an outcome of direct 
microbial insult or indirect outcomes of disease in other organs. HPS is a recognized 
clinical problem, which is associated with liver dysfunction. Human patients with end 
stage liver diseases, such as advanced liver cirrhosis, are highly susceptible to HPS. 
There is growing evidence that PIMs, recruited in biliary dysfunction, play important 
roles in HPS. PIMs are normally present in domestic animal species such as cattle, 
horses, sheep and goat and make these host species highly susceptible to lung 
inflammation and diseases. Because PIMs can be recruited in species such as rats 
following bile duct ligation or during general physiological stress, it is critical to establish 
their precise contributions in lung inflammation. Therefore, I propose to conduct a series 
of experiments to characterize recruited PIMs in a rat model of bile duct ligation and use 
this model to investigate PIMs’ contributions to lung inflammation associated with 
biliary cirrhosis.  
 
My first experiment is designed to understand the PIM recruitment in rats following 
ligation of their bile ducts and to establish a method to deplete recruited PIMs. This 
experiment also includes examination of lung tissues for the expression of selected 
inflammatory cytokines to assess direct effects of PIM recruitment on lung physiology. 
The second experiment is designed to understand the contributions of PIMs in LPS-
induced lung inflammation. This will be accomplished by removing recruited PIMs with 
gadolinium chloride before LPS challenge and compare LPS-induced lung inflammation 
in rats with intact PIMs. The proposed experiments are expected to yield data that will 
enhance our understanding of basic biology and inflammatory functions of PIMs.  
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5. MATERIALS and METHODS 
Table 5.1. Reagents and their sources 
Reagents                    Source 
Anti-rat goat polyclonal TNF-α antibody                         Santa Cruz Biotec., USA 
Anti-rat goat polyclonal IL-1β antibody                           Santa Cruz Biotec., USA 
Anti-porcine mouse monoclonal TGF-β antibody            R & D Systems, Inc., USA 
Anti-mouse goat polyclonal IL-10 antibody                     Santa Cruz Biotec., USA 
Anti-rat mouse monoclonal macrophage antibody           Serotec, USA 
Purified hamster anti mouse/rat TNF- α (ELISA) BD Pharmingen, 
Biotin rabbit anti-mouse/rat TNF-α (ELISA) BD Pharmingen 
Recombinant rat TNF-α (ELISA) BD Pharmingen 
Anti-rat IL-1β antibody (ELISA) R & D Systems, Inc., USA 
Biotinylated anti-rat IL-1β antibody (ELISA) R & D Systems, Inc., USA 
Recombinant rat IL-1β (ELISA) R & D Systems, Inc., USA 
Monoclonal anti-TGF-β2 antibody (ELISA) R & D Systems, Inc., USA 
TGF-β2 biotinylated antibody (ELISA) R & D Systems, Inc., USA 
Recombinant human TGF-β2 (ELISA) R & D Systems, Inc., USA 
Purified anti-rat IL-10 (ELISA) BD Pharmingen 
Biotin mouse anti-rat IL-10(ELISA)  BD Pharmingen 
Recombinant rat IL-10 (ELISA) BD Pharmingen 
Purified anti-rat MCP-1 (ELISA) BD Pharmingen 
Biotin anti-rat MCP-1 (ELISA) BD Pharmingen 
Recombinant rat MCP-1 (ELISA) BD Pharmingen 
Peroxidase color development kit (immunostaining)       Vector laboratories, USA 
Methyl green                                                                     Vector laboratories, USA 
Ketamine hydrochloride Vetrepharm, Canada Inc. 
Xylazine Bayer, Canada 
Gadolinium chloride Sigma Co. 
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5.1. Animals 
 
The experimental protocols were approved by the University of Saskatchewan 
Committee on Animal Care Assurance. Specific pathogen free 350-400 gram rats were 
procured from Charles River Laboratories, Canada. Rats were acclimatized for a period 
of one week before the experiment. 
 
5.2. Experimental Design 
Table 5.2. Treatment groups 
Group Treatment 
Control                                             (N=5)   No surgery and no treatment 
Sham                                                (N=3) Sham operation and no treatment 
Bile duct ligated (BDL)                   (N=4)     Bile duct ligation and no treatment 
BDL & Gadolinium chloride (GC)  (N=5)     Bile duct ligation and administration of 
gadolinium chloride (10 mg/kg) intravenously 
Control + E. coli LPS                       (N=6) Control rats injected with E. coli LPS  
BDL+ E. coli LPS                            (N=6)     Bile duct ligation and administration of E. coli
LPS (0.1mg/kg iv)  
BDL+ GC + E. coli LPS                  (N=5)     Bile duct ligation, administration of GC and 
then treatment with LPS (0.1mg/kg iv) 6 hrs  
after GC (10 mg/kg) intravenously 
BDL+ GC + E. coli LPS                  (N=5)     Bile duct ligation, administration of GC and 
then treatment with LPS (0.1mg/kg iv) 48 hrs  
post-GC treatment (10 mg/kg) intravenously 
 
5.3. Operating Procedures 
 
By using sterile techniques, a mid line incision was made, the common bile duct was 
identified and ligated at two points 5 mm apart by using non absorbable suture material 
(Nylon, 4-0). The common bile duct was then resected in the middle of two ligatures. In 
sham operated animals, the common bile duct was identified and separated from the 
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surrounding soft tissue with out ligation and resection. The surgery was done using 
intraperitoneal anesthesia induced with the combination of ketamine (80 mg/kg) and 
xylazine (10 mg/kg). After surgeries, rats were allowed free access to water and rat chow 
and allowed to survive for 4 weeks. Rats were observed every 6 hours and really sick rats 
were humanely euthanized. 
 
5.4. Sampling and Processing   
 
5.4.1. Lung tissue processing: 
 
5.4.1.1. Light Microscopy: 
 
      A. Histopathology: Blocks from left lung were fixed in 4% paraformaldehyde for 24 
hours at 4°C. The tissues were transferred to PBS, dehydrated in ascending 
concentrations of ethanol and cleared in xylene followed by embedding in paraffin. Five 
micron sections were cut from each tissue block and placed on silane-coated slides. They 
were dewaxed in 2 changes of xylene and stained with hematoxylin-eosin for histologic 
examination. 
 
      B. Immunohistology: Sections were de-waxed and rehydrated in graded ethanol series 
followed by incubation with 5% hydrogen peroxide in methanol to remove endogenous 
peroxide. Sections were treated with pepsin (2 mg/ml 0.01 N hydrochloric acid) for 45 
minutes for antigen retrieval and then incubated with 1% bovine serum albumin to block 
non-specific sites. Sections were treated with primary [ TNF-α, IL-1β, MCP-1, IL-10, 
TGF-β2 and anti-macrophage (ED-1)] antibodies and with appropriate horseradish 
peroxide-conjugated secondary antibodies for 60 and 30 minutes respectively followed 
by color development using a commercial kit ( Vector Laboratories, Canada). Controls 
included incubation of sections with only secondary antibody or with only color 
development reagent. Another control was to stain some of the sections with anti-von 
Willebrand Factor (vWF) antibody which recognizes vascular endothelium. Finally, 
sections were counter-stained with methyl green. 
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      5.4.1.2. Immuno-electronmicroscopy: 
      Lung pieces of approximately 1mm³ sizes were fixed in 2% paraformaldehyde with 0.1% 
glutaraldehyde for 3 hours at 4°C. The fixed tissues were rinsed in 0.1 M sodium 
cocadylate buffer and dehydrated in graded ethanol series. These pieces were infiltrated 
with LR White Resin (EM Sciences, USA) and polymerized in polythene beam capsules 
under ultraviolet light for 48 hours at -1°C.One micron sections were prepared and 
stained with toluidine blue to select appropriate areas for ultra-microtomy. Ultra thin (0.1 
micron) sections were cut from the tissue blocks and placed on nickel grids. 
 
  Nickel grids with sections were floated on a blocking buffer (1% bovine serum albumin 
and 0.1% Tween-20 in tris-buffered saline; pH 7.9) for 30 minutes followed by 
incubation with primary (ED-1, TNF-α, IL-1β and MCP-1) antibodies for one hour. 
Tissue sections were rinsed three times for five minutes each in Tris-buffered saline and 
incubated with appropriate gold conjugated secondary antibodies (1:100) for one hour 
followed by staining with 2% aqueous uranyal acetate and then lead citrate.       
 
 5.4.1.3. RT-PCR 
 
A. RNA isolation  
Total RNA was isolated from lung tissues of rat by sequential extraction with TRIzol 
reagent (Invitrogen) followed by treatment with RNase-free DNase I (Qiagens) and 
purification by RNeasy mini columns (Qiagens) according to manufacturer’s instructions. 
RNA integrity was confirmed by agarose gel electrophoresis, and RNA was quantified by 
spectrophotometric analysis.  
 
B. Reverse transcription – PCR 
 Superscript III one-step RT-PCR system with Platinum Taq DNA polymerase 
(Invitrogen) was used for semi-quantitative analysis of the levels of expression of MCP-
1, pro-inflammatory cytokines (IL-1β, TNF-α) and anti-inflammatory cytokines (IL-10, 
TGF-β) in lung tissues of variously treated rats. Reactions were performed as directed by 
the manufacturer, using the oligonucleotide pairs as below: 
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Gene   Forward primer   Reverse primer 
MCP-1 5’-CGCTTCTGGGCCTGTT-3’ and 5’-GAAGTGCTTGAGGTGGT-3’ 
IL-1β 5’-TTGCCCGTGGAGCTTC-3’ and 5’-CGGGTTCCATGGTGAAC-3’ 
TNF-α        5’-GCACAGAAAGCATGATCC-3’and 5’-GTGGGTGAGGAGCACAT-3’ 
IL-10          5’-GCTGCGACGCTGTCAT-3’ and 5’-GCGCTGAGCTGTTGCT-3’ 
TGF-β2 5’- CATCCCGCCCACTTTC-3’ and 5’-CATGCCCCAGCACAGA-3’ 
 
Each reaction was performed using 10 ng of total RNA and thermocycler was 
programmed for reverse-transcription at 55 °C for 30 min, initial denaturation of the 
cDNA at 94 °C for 2 min, 30 amplification cycles, each of which consisted of 94 °C for 
15 sec, 59 °C for 30 sec, and 68 °C for 1 min followed by a final extension at 68 °C for 5 
min. To ensure lack of DNA contamination 2 units of Platinum Taq DNA polymerase 
was substituted for the Superscript III RT/Platinum Taq mixture in the reaction. A 
negative control reaction consisted of all the components of the reaction mixture except 
RNA. Amplified PCR products were electrophoresed on a 1 % TAE-agarose gel, stained 
with ethidium bromide and photographed under UV light. 
 
      5.4.1.4. Enzyme-linked immunosorbent assay (ELISA): 
      Lung tissues were homogenized in 10X HBSS solution containing proteinase-K inhibitor 
cocktail. Homogenates were collected in eppendorf tubes and centrifuged at 4°C for 20 
minutes at 25, 000 RCF. Supernatants were collected in eppendorf tubes and stored at -
80°C. Cytokine concentrations in supernatants were determined using ELISA.  For the 
ELISA, wells of microtitre plate were coated with 50 µl of capture antibody (diluted with 
sodium phosphate buffer) and incubated at 4°C overnight. Next day, capture antibody 
was removed and 200 µl of blocking buffer (1% BSA in PBS) was added to each well and 
incubated at 37°C for one hour. Blocking buffer was removed and wells were washed 
with PBST (PBS containing Tween-20). Standards and samples were diluted in blocking 
buffer-Tween and 100 µl of standards and samples were added to the wells and incubated 
at 37°C for 2 hours. After removing standards and samples, wells were washed with 
PBST and 100 µl of detection antibody was added to each well after dilution with 
blocking buffer-Tween. Plate was incubated at 37°C   for one hour. Detection antibody 
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was removed and wells were washed and 100 µl of streptavidin-HRP (1:2500 in blocking 
buffer-Tween) was added to each well and incubated at room temperature for 30 minutes. 
Wells were washed thoroughly with PBST and 100 microlitres of substrate (TMB) was 
added to each well and incubated in dark at room temperature for 20 minutes. On color 
development, reaction was stopped by adding 50 µl of 0.5 M sulphuric acid to each well. 
Readings were then taken at 450 nm wavelength.  
 
5.5. Statistical analysis: 
Analysis was done using a statistical software package (SPSS 12.0 for windows). Mean 
differences among groups were compared by using one-way analysis of variance 
followed by post-hoc analyses with Fisher’s LSD test.  
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6. RESULTS 
 
6.1. Results (Experiment-1) 
 
6.1.1.Clinical response to bile duct ligation: Initially, I encountered a mortality rate of 
50% in rats subjected to bile duct ligation. However, with improvement in my surgical 
and post-operative skills, the mortality rate came down to 15%, which is lower than the 
rate reported by other investigators. All bile duct ligated rats became dull and 
inactive up to two days after bile duct ligation.Their food and water intake decreased and 
all rats lost up to 50-100 grams of weight over the period of one week. After one week, 
rats started eating and drinking normally and started gaining weights and reached their 
original weights (sometimes exceeding original weights) in 3-4 weeks after bile duct 
ligation. However, their urine and mucous membranes became icteric. Nearly four weeks 
after the ligation, a swelling was evident upon palpation in anterior part of the abdomen 
in most of the rats. Sham operated rats continued to grow normally even after the surgery. 
 
6.1.2. Histopathology: Control rats and sham operated rats showed normal lung 
morphology (Figure 6.1.1.A-B, F). In contrast, bile duct ligated rats showed increased 
number of mononuclear cells in the alveolar septa (Figure 6.1.1.C-E). Gadolinium 
chloride treatment of BDL rats resulted in decrease in the number of mononuclear cells 
(Figure 6.1.1.D). Because lungs of sham-operated rats appeared similar to the controls, I 
used only the control rats in the analyses.  
 
6.1.3. ED-1 Immunocytochemistry 
 
6.1.3.1. Immunohistology for ED-1: Immunohistology demonstrated staining of septal 
cells with ED-1. Bile duct ligated rats showed increase in the number of ED-1 positive 
cells in the alveolar septa (Figure 6.1.2.B) compared to the sham-operated rats (Figure 
6.1.2.A). However, BDL rats treated with gadolinium chloride showed a decrease in 
number of ED-1 positive cells (Figure 6.1.2.C) compared to that in BDL rats. 
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6.1.3.2. Immuno-electron microscopy for ED-1: Lung sections stained with ED-1 
antibody and gold-conjugated secondary antibodies showed labeling in large 
mononuclear cells resembling macrophages (Figure 6.1.3). These ED-1 positive cells 
were attached to capillary endothelium and contained lysosomes.  
 
6.1.3.3. Numerical counts of ED-1 positive cells: Following confirmation that ED-1 
antibody recognizes sequestered PIMs, we performed counts of cell stained with ED-1 
antibody. Bile duct ligation induced increase in the number of ED-1 positive cells 
compared to that in sham operated rats (p=0.002) (Figure 6.1.4). There were very few 
ED-1 positive cells in the alveolar septa of sham-operated rats. Gadolinium chloride 
treatment of BDL rats decreased the numbers of ED-1 positive cells compared to those in 
BDL rats (p=0.061) (Figure 6.1.4).  
 
6.1.4. MCP-1 Expression 
 
6.1.4.1. MCP-1 mRNA expression: Total RNA extracted from the lungs of variously 
treated rats was subjected to RT-PCR for MCP-1. Samples devoid of RNA as well as 
those treated with DNase did not show any amplified product. RT-PCR for GAPDH 
showed bands of equal size indicating uniform loading of RNA samples. PCR products 
separated on 1% agarose gel showed differential expression of MCP-1 transcripts. Gel 
densitometry showed that bile duct ligation increased MCP-1 mRNA expression 
compared to control rats (p=0.017). Gadolinium chloride treatment of BDL rats also 
resulted in increase in MCP-1 transcript levels in comparison to the control and BDL rats 
(p=0.000 & 0.000 respectively) (Figure 6.1.7.A). 
 
6.1.4.2. MCP-1 protein expression: MCP-1 protein expression in lungs was measured 
with ELISA. MCP-1 concentrations were higher in BDL rats compared to that in control 
rats (p=0.089). Gadolinium chloride treated BDL rats showed higher concentrations of  
MCP-1 compared to the control rats (p=0.048) (Figure 6.1.7.B). 
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6.1.4.3. Immunohistochemistry for MCP-1: Staining of lung sections with MCP-1 
antibody showed only focal staining in the alveolar septa of control rats and sham 
operated rats (Figure 6.1.5.A & B). However, lung sections from rats after 2 weeks of 
bile duct ligation showed uniform MCP-1 staining in the alveolar septa (Figure 6.1.5.C). 
Although pattern of MCP-1 staining at 4 weeks post-BDL was similar to the 2 week rats, 
the staining intensity was increased (Figure 6.1.5.D). 
 
6.1.4.4. Immuno-electron microscopy for MCP-1: Lung sections stained with MCP-1 
antibody and then gold conjugated secondary antibodies showed specific staining for 
MCP-1 in PIMs (Figure 6.1.6.A) and endothelial cells (Figure 6.1.6.B). 
 
6.1.5. IL-1β expression 
 
6.1.5.1. IL-1β mRNA expression: Total RNA extracted from rat lungs was amplified 
with RT-PCR for IL-1β. Densitometric analyses showed no differences in the levels of 
IL-1β transcripts between different groups (Figure 6.1.8.A). 
 
6.1.5.2. IL-1β protein expression: There were no differences in IL-1β concentration 
between control rats, BDL rats and gadolinium chloride treated BDL rats (Figure 
6.1.8.B). 
 
6.1.6. TNF-α expression 
 
6.1.6.1. TNF-α mRNA expression: Densitometry of gel bands showed no differences in 
the levels of TNF-α transcript between control and BDL rats. However, lungs of rats 
treated with gadolinium chloride showed increase in TNF-α transcript levels compared to 
the BDL and  control rats (p=0.004 in both groups) (Figure 6.1.9.A). 
 
6.1.6.2. TNF-α protein expression: TNF-α protein concentrations were not different 
between control rats, BDL rats and gadolinium chloride treated BDL rats (Figure 
6.1.9.B). 
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6.1.7. IL-10 expression 
 
6.1.7.1. IL-10 mRNA expression: Gel densitometry showed increased levels of IL-10 
transcripts in lungs of BDL rats compared to control rats (p=0.000). Gadolinium chloride 
treatment of rats increased IL-10 expression in BDL rats compared to that in BDL or 
control rats (p=0.000 in both groups) (Figure 6.1.10.A). 
 
6.1.7.2. IL-10 protein expression: There was no difference in IL-10 concentration 
between control rats, BDL rats and gadolinium chloride treated BDL rats (Figure 
6.1.10.B). 
 
6.1.8. TGF-β expression 
 
6.1.8.1. TGF-β mRNA expression: Densitometry of gels showed no difference in TGF-
β transcripts between BDL or control rats. However, gadolinium chloride treated rats 
showed increase in TGF-β mRNA compared to the BDL or control rats (p=0.000 & 0.01 
respectively) (Figure 6.1.11.A). 
 
6.1.8.2. TGF-β mRNA expression: There was no difference in TGF-β concentration 
between control rats, BDL rats and gadolinium chloride treated BDL rats (Figure 
6.1.11.B). 
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Histopathology: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1.1:  H & E staining. There is extensive infiltration of mononuclear cells 
(arrows) in the alveolar septa of bile duct ligated (BDL) rats (C) compared to that in 
control (A) and sham operated (B) rats. However, number of mononuclear cells in the 
alveolar septa decreases in BDL rats after treatment with gadolinium chloride (D). 
High magnification views of lung sections from BDL (E) and a control (F) rat clearly 
show accumulation of large mononuclear cells in the septa of the former. Bar = 
25µm.   
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Immunohistology for ED-1: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1.2: Immunohistology for macrophages (ED-1 staining). There is increase in the 
number of ED-1 positive cells (arrows) in bile duct ligated (BDL) rats (B) compared 
to that in sham operated rats (A).However, number of ED-1 positive cells decrease in 
BDL rats after gadolinium chloride treatment (C). Bar = 25 µm.   
 
 
 
 
 
A 
C
BA
A B
C 
 25
 
Immuno-electron microscopy for ED-1: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1.3: An immuno-electron micrograph showing ED-1 labeling (arrows) in a 
pulmonary intravascular macrophage (PIM) but not in alveolar septum (S) of a BDL 
rat. L: lysosome. Bar = 1 micron 
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Figure 6.1.4: ED-1 counts: Number of ED-1 cells in BDL and BDL+GC groups are 
higher compared to the control (p<0.002). BDL rats also contain higher numbers of 
ED-1 cells compared to BDL rats treated with GC (p=0.06).  
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Immunohistology for MCP-1:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1.5: MCP-1 immunohistochemistry: Lung sections stained with MCP-1 
antibody show focal purple staining (arrows) for MCP-1 in the alveolar septa in the 
control (A) and the sham-operated rats (B).However, there is uniform staining for 
MCP-1 in 2 week BDL rats (C) and 4 week BDL rats (D). Bar = 25 µm.  
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Immuno-electron microscopy for MCP-1: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1.6: MCP-1 immuno-electron microscopy: An electron micrograph showing 
MCP-1 labeling (arrows) in a PIM (A) and an endothelial cell (E; B). Ep: epithelium; 
S: alveolar septum; AS: alveolar space. Bar = 1 micron 
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Figure 6.1.7: RT-PCR (A) detected higher levels of MCP-1 mRNA in BDL+GC rats 
compared to the controls and BDL (p=0.000 for both) and in BDL rats in comparison 
to the controls (p=0.017). ELISA (B) detected higher concentrations of MCP-1 
protein in BDL (p=0.089) and BDL+GC (p=0.048) rats compared to the controls.  
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IL-1β Expression: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1.8: RT-PCR (A) detected IL-1β mRNA and semi-quantitative densitometry 
showed no differences between the groups (p=0.76 and p=0.11). ELISA (B) detected 
no differences in concentrations of IL-1β protein between control and BDL (p=0.122) 
or BDL and BDL+GC (p=0.443) groups.  
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TNF-α Expression: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1.9: RT-PCR (A) detected TNF-α mRNA and semi-quantitative densitometry 
showed higher levels in BDL+GC rats compared to the controls (p=0.004) and the 
BDL rats (p=0.004).  ELISA (B) detected no differences in concentrations of TNF-α 
protein between control and BDL (p=0.398) or BDL and BDL+GC (p=0.405) 
groups.  
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IL-10 Expression: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1.10: RT-PCR (A) detected higher levels of IL-10 mRNA in BDL+GC rats 
compared to the control (p=0.000) or BDL (p=0.000) rats. ELISA (B) detected no 
differences in concentrations of IL-10 protein between control and BDL (p=0.331) or 
BDL and BDL+GC (p=0.539) groups.  
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TGF-β Expression: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1.11: RTPCR (A) detected increased expression of TGF-β mRNA in BDL+GC 
rats compared to the control (p=0.01) or BDL (p=0.000) rats. ELISA (B) detected no 
differences in concentrations of TGF-β protein between control and BDL (p=0.672) 
or BDL and BDL+GC (p=0.282) groups.  
.  
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6.2.   Results (Experiment-2) 
 
6.2.1.Clinical response to bile duct ligation: All bile duct ligated rats became dull and 
inactive up to two days after bile duct ligation.Their food and water intake decreased and 
all rats lost up to 50-100 grams of weight over the period of one week. After one week, 
rats started eating and drinking normally and started gaining weights and reached their 
original weights (sometimes exceeding original weights) in 3-4 weeks after bile duct 
ligation. However, their urine and mucous membranes became icteric. Close to four 
weeks after bile duct ligation, a swelling was evident up on palpation in anterior part of 
the abdomen in most of the rats. Sham operated rats continued to grow normally even 
after the surgery. 
 
6.2.2. Clinical response to LPS challenge: The data are depicted in Table 6.1. Rats 
challenged with LPS after 4 weeks of the ligation became very dull and inactive 
immediately after the LPS injection. These rats showed increased and labored respiration 
and piloerection. All rats started to defecate and urinate. There was vocalization and 
convulsions before death. All of the rats with bile duct ligation died within three hours of 
the LPS challenge. In gadolinium chloride treated BDL rats only one rat died within three 
hours of the LPS challenge and 9 rats survived till 6 hours after LPS challenge (10% 
mortality). These rats also showed much mild clinical signs after the LPS challenge.   
 
6.2.3. Histopathology: LPS challenge of control and BDL rats showed accumulation of 
mononuclear cells in the alveolar septa as well as increase in the thickness of the septa 
(Figure 6.2.1.A & B). It appeared that gadolinium chloride treatment of BDL rats prior to 
LPS challenge resulted in reduced infiltration of mononuclear cells and near normal 
alveolar septal thickness compared to that in LPS challenged BDL rats (Figure 6.2.1.C & 
D). 
 
6.2.4. ED-1 Immunocytochemistry: 
 
6.2.4.1. Immunohistology for ED-1: Immunohistology demonstrated staining of lung 
septal cells with ED-1. LPS treatment of BDL rats showed increase in the number of ED-
1 positive cells in the alveolar septa (Figure 6.2.2.B) compared to the LPS-treated control 
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rats (Figure 6.1.2.C). Control rats challenged with LPS showed near normal number of 
ED-1 positive cells (Figure 6.2.2.A). Gadolinium chloride treatment of BDL rats prior to 
LPS challenge resulted in decrease in the number of ED-1 positive cells (Figure 6.2.2.C 
& D) compared to that in LPS challenged BDL rats. 
 
6.2.4.2. ED-1 positive cell count: Intravenous infusion of LPS in BDL rats caused an 
increase in the number of ED-1 positive cells in comparison to the control or LPS-
challenged control rats (p=0.000 in both groups). Gadolinium chloride treatment of BDL 
rats 6 hours or 48 hours prior to LPS challenge resulted in decrease in the number of ED-
1 positive cells as compared to that in LPS challenged BDL rats (p=0.039 & 0.002 
respectively; Figure 6.2.3).  
 
6.2.5. Immunohistochemistry for E. coli LPS: Anti-LPS antibody was used to confirm 
the LPS in the lung sections from rats in all the LPS-treated groups. There was less 
staining for LPS in the alveolar septa of control rats challenged with E. coli LPS (Figure 
6.2.4.A). In contrast, LPS treated BDL rats showed extensive staining for LPS in the 
alveolar septa as well as in mononuclear cells present in the blood vessels (Figure 
6.2.4.B). 
 
6.2.6. MCP-1 Expression 
 
6.2.6.1. MCP-1 mRNA expression: Total RNA extracted from the lungs of rats was 
subjected to RT-PCR for MCP-1. PCR products separated on 1% agarose gel showed 
differential expression of MCP-1 transcripts. Gel densitometry showed that LPS 
treatment of BDL rats increased levels of MCP-1 mRNA compared to the control or LPS-
treated control rats (p=0.000 & 0.01 respectively). BDL rats treated with gadolinium 
chloride 6 hours or 48 hours prior to LPS challenge showed reduced MCP-1 expression 
compared to that in LPS challenged BDL rats (p=0.017 & 0.000 respectively) (Figure 
6.2.5.A).   
 
6.2.6.2. MCP-1 protein expression: LPS treatment of BDL rats caused increase in lung 
concentrations of MCP-1 compared to the control or LPS treated control rats (p=0.000 
both). Gadolinium chloride treatment of BDL rats 6 hours or 48 hours before LPS 
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challenge reduced MCP-1 protein expression compared to LPS-treated BDL rats 
(p=0.042 & 0.000 respectively) (Figure 6.2.5.B). 
 
6.2.7. IL-1β Expression 
 
6.2.7.1. IL-1β mRNA expression: Densitometric analysis of gels showed higher levels 
of IL-1β mRNA transcripts in LPS-challenged BDL rats compared to control rats 
(p=0.012) but not LPS-challenged control rats (p=0.746). Gadolinium chloride treatment 
of BDL rats at 6 hours or 48 hours prior to LPS administration did not affect IL-1β 
expression compared to LPS-challenged BDL rats (p=0.712 & 0.509 respectively) 
(Figure 6.2.6.A). 
 
6.2.7.2. IL-1β protein expression: BDL rats challenged with LPS contained increased 
concentrations of IL-1β in their lungs in comparison to the control rats (p=0.000) and 
LPS-challenged control rats (p=0.000). Although gadolinium chloride treatment of BDL 
rats at 6 hours prior to LPS challenge did not affect IL-1β concentration (p=0.455) 
compared to BDL+LPS rats but a treatment 48 hours prior to the LPS challenge reduced 
IL-1β concentrations in lungs (p=0.008) (Figure 6.2.6.B). 
 
6.2.7.3. Immuno-electron microscopy for IL-1β: Staining of lung sections with IL-1β 
antibody and then gold conjugated secondary antibodies showed IL-1β labeling in PIM 
(Figure 6.2.7). 
 
6.2.8. TNF-α Expression 
 
6.2.8.1. TNF-α mRNA expression: Gel densitometry revealed lower levels of the 
mRNA transcripts in lungs of control rats compared to all the groups except the LPS-
challenged control rats (p=0.193). Higher levels of TNF-α mRNA in LPS challenged 
BDL rats were detected compared to control rats (p=0.006) but not LPS-challenged 
control rats (p=0.062). Compared to BDL+LPS rats, gadolinium chloride treatment of 
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BDL rats 6 hours or 48 hours prior to the LPS injection did not affect TNF-α mRNA 
expression (p=0.499, p= 0.297 respectively) (Figure 6.2.8.A). 
 
6.2.8.2. TNF-α protein expression: Lungs from BDL rats treated with LPS showed 
increased concentrations of TNF-α compared to control rats (p=0.000) and LPS-
challenged control rats (p=0.000). Gadolinium chloride treatment of BDL rats 48 hours 
(p=0.001) but not 6 hours (p=0.572) prior to LPS challenge resulted in decreased lung 
concentrations of TNF-α compared to LPS challenged BDL rats (Figure 6.2.8.B). 
 
6.2.8.3. Immuno-electron microscopy for TNF-α: Immunogold electron microscopy 
showed TNF-α labeling in PIMs (Figure 6.2.9). 
 
6.2.9. IL-10 Expression 
 
6.2.9.1. IL-10 mRNA expression: Densitometry showed increased expression of IL-10 
mRNA in LPS-challenged BDL rats compared to control rats (p=0.000) and LPS-
challenged control rats (p=0.000). Gadolinium chloride administration in BDL rats at 6 
hours or 48 hours before LPS challenge suppressed IL-10 expression compared to LPS-
treated BDL rats (p=0.038 & 0.000 respectively) (Figure 6.2.10.A). 
 
6.2.9.2. IL-10 protein expression: There was increase in IL-10 concentration in lungs of 
LPS-treated BDL rats compared to the control (p=0.018) or LPS-treated control rats 
(p=0.002). IL-10 concentration in lungs of control rats was similar to those of LPS-
treated control rats (p=0.353). Gadolinium chloride treatment of BDL rats 48 hours 
(p=0.030) but not 6 hours (p=0.420) before the LPS challenge decreased concentration 
of IL-10 in lungs in comparison to LPS-challenged BDL rats (Figure 6.2.10.B). 
 
6.2.10. TGF-β Expression 
 
6.2.10.1. TGF-β mRNA expression: Compared to the control rats, TGF-β expression 
was increased in lungs of LPS-challenged BDL (p=0.000) or LPS-challenged control rats 
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(p=0.001). Gadolinium chloride treatment of BDL rats at 48 hours (p=0.000) but not at 6 
hours (p=0.182) prior to the LPS challenge suppressed lung transcription of TGF-β 
compared to BDL+LPS rats (Figure 6.2.11.A). 
 
6.2.10.2. TGF-β protein expression: Lung homogenates from LPS-treated control rats 
showed lower TGF-β concentrations compared to all other groups. Gadolinium chloride 
treatment of BDL rats prior to LPS challenge had no effect on TGF-β concentration 
compared to LPS treated BDL rats (Figure 6.2.11.B). 
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Table 6.1: Clinical response to LPS challenge  
 
Treatment Number of rats 
(N) 
Number of rats died within 
6 hours of LPS challenge 
Mortality 
(%) 
Control+LPS 5 0 0 
BDL+LPS 6 6 100 
BDL+GC(6H)+LPS 5 1 20 
BDL+GC(48H)+LPS 5 0 0 
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Histopathology (LPS challenge): 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2.1: H & E staining: LPS challenge of BDL rats (B) resulted in more vascular 
congestion (arrows) compared to LPS-challenged control rats (A). Gadolinium 
chloride treatment of BDL rats 6 hours (C) or 48 hours (D) prior to LPS challenge 
resulted in less infiltration of mononuclear cells and near normal lung histology. High 
magnification views of lung sections from LPS-challenged control rats (E) and LPS-
challenged BDL rats (F) show differences in vascular congestion (arrows) between 
the two treatments. Bar = 25 µm.  
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Immunohistology for ED-1 (LPS challenge): 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2.2: Immunohistology for macrophages (ED-1 staining): LPS challenge of BDL 
rats (B) resulted in dramatic increase in the number of ED-1 positive cells (arrows) 
compared to that in LPS challenged control rats (A) and BDL rats treated with 
gadolinium chloride at 6 hours (C) or 48 hours (D) before the LPS treatment. Bar = 
25µm.  
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ED-1 Positive Cell Count:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2.3: ED-1 cell counts:. Groups bearing superscripts (for example ‘a’) differ 
from the groups carrying different superscripts, (for example ‘b’ or ‘c’) while the 
groups with similar superscripts did not differ. See “Results” for details. 
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Immunohistology for LPS: 
 
 
 
 
 
  
 
Figure 6.2.4: Lung sections stained with anti-LPS antibody show negligible staining for 
LPS (arrows) in the alveolar septa of control rats challenged with LPS (A). However, 
BDL rats challenged with LPS show extensive staining for LPS in the alveolar septa 
(arrows) as well as in mononuclear cells present in the blood vessel (double arrows) 
(B). Micrometer bar = 25µm. 
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MCP-1 Expression: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2.5: MCP-1 mRNA (A) and protein (B) expression: Groups bearing 
superscripts (for example ‘a’) differ from the groups carrying different superscripts, 
(for example ‘b’ or ‘c’) while the groups with similar superscripts did not differ. For 
detail see “Results”. 
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IL-1β Expression: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2.6:  IL-1β mRNA (A) and protein (B) expression: Groups bearing 
superscripts (for example ‘a’) differ from the groups carrying different superscripts, 
(for example ‘b’ or ‘c’) while the groups with similar superscripts did not differ. For 
detail see “Results”. 
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Immuno-electron microscopy for IL-1β:  
 
 
 
 
Figure 6.2.7: An immuno-electron micrograph showing IL-1β labeling (arrows) in a 
pulmonary intravascular macrophage (PIM) as well as capillary endothelium (E: 
double arrows). AS: alveolar space. Bar = 1 micron
AS 
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E
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TNF-α Expression: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2.8: TNF-α mRNA (A) and protein (B) expression: Groups bearing 
superscripts (for example ‘a’) differ from the groups carrying different superscripts, 
(for example ‘b’ or ‘c’) while the groups with similar superscripts did not differ. For 
detail see “Results”. 
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Immuno-electron microscopy for TNF-α:  
 
 
 
 
 
Figure 6.2.9: An immuno-electron micrograph showing TNF-α labeling (arrows) in a 
PIM as well as capillary endothelium (double arrows). AS: alveolar space; E: 
endothelium; L: lysosome; AS: alveolar space. Bar = 1 micron 
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IL-10 Expression: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2.10: IL-10 mRNA (A) and protein (B) expression: Groups bearing 
superscripts (for example ‘a’) differ from the groups carrying different superscripts, 
(for example ‘b’ or ‘c’) while the groups with similar superscripts did not differ. For 
detail see “Results”. 
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TGF-β Expression: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2.11: TGF-β mRNA (A) and protein (B) expression: Groups bearing 
superscripts (for example ‘a’) differ from the groups carrying different superscripts, 
(for example ‘b’ or ‘c’) while the groups with similar superscripts did not differ. For 
detail see “Results” 
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7. DISCUSSION: 
 
7.1. BDL as a model of recruited PIMs 
Biliary cirrhosis induced by bile duct ligation causes permanent recruitment of 
intravascular macrophages in rats (Chang and Ohara,1994).  Bile duct ligation model in 
rats has been used to study the mechanisms of HPS in human patients with liver cirrhosis 
(Nunes et al., 2001), (Sztrymf et al., 2004), (Rabiller et al., 2002) as well as to study 
biology of PIMs (Chang and Ohara,1994). I am interested in investigating the role of 
PIMs in the development of HPS as well as pulmonary diseases in other domestic 
species. Therefore, I used BDL model to study these aspects.  
 
Initially, I encountered high mortality in rats following ligation of their bile ducts. 
However, with improvement of my surgical and post-operative skills, the mortality rates 
came below 20%, which are similar to those reported by other workers (Nunes et al., 
2001). I found that recruited cells are monocytes/macrophages as indicated by ED-1 
antibody. ED-1 antibody recognizes a single chain glycoprotein of 110 kD. This protein 
is normally expressed on the lysosomal membrane of monocytes/macrophages. Electron-
microscopy further confirmed that recruited cells contained ED-1, which established 
recruited cells as macrophages. Therefore, BDL rats in my experiments showed 
recruitment of PIMs. Although intravascular recruitment of PIMs in BDL rats has been 
previously demonstrated by Chang and colleagues (Chang and Ohara, 1994), these cells 
have not been immunophenotyped. Thus, ED-1 staining in recruited PIMs confirms their 
identity as macrophages. It appears that recruited PIMs in BDL rats form much tighter 
adhesion with capillary endothelium compared to the transiently recruited PIMs 
following a single intraperitoneal E. coli injection (Singh and Atwal, 1997). Therefore, 
BDL rats may be a useful model to investigate PIM biology in liver dysfunction as well 
as in species in which these cells are normally present.  
 
The mechanisms of recruitment of PIMs following bile duct ligation remain unknown. 
Macrophage recruitment is regulated by a variety of chemoattractants such as MCP-1. 
Because MCP-1 is one of the most potent chemokines for lung recruitment of monocytes 
and macrophages (Maus et al., 2001), I examined its expression in normal and BDL rats. 
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MCP-1 exists in two isoforms (13kD & 9kD) (Jiang et al., 1991). MCP-1 mRNA as well 
as protein expression was increased in lungs of BDL rats compared to the normal rats. 
MCP-1 was localized in septal cells including recruited PIMs. These data suggest that 
MCP-1 may play a role in PIM recruitment in BDL rats. However, this does not preclude 
the possibility that other chemokines such as MIP-2 or CINC-1 may also be promoting 
accumulation of PIMs in BDL rats. Furthermore, I will need to perform MCP-1 blocking 
experiments to demonstrate specific contributions of MCP-1 in PIM recruitment in BDL 
rats. 
 
Because BDL rats are used as a model for HPS and they may also be useful in study of 
PIMs in domestic animal species, it is important to examine baseline cytokine expression 
in lungs and compare it to lungs from normal rats. I selected two pro-inflammatory (IL-
1β & TNF-α) and two anti-inflammatory (IL-10 & TGF-β) cytokines. There were no 
significant differences in the mRNA and protein expression of IL-1β, TNF-α and TGF-β 
between control and BDL rats. Although IL-10 mRNA expression was altered, the 
protein concentrations were similar between the two groups. Because the protein is the 
functional product of gene transcription, I conclude that compared to the control rats PIM 
recruitment in BDL rats did not alter lung expression of various cytokines. Therefore, the 
BDL rats may be a valid model to investigate biology of PIMs in domestic animals. 
 
7.2. PIM depletion with gadolinium chloride 
To directly evaluate the role of recruited PIMs, we should be able to deplete these cells to 
examine lung inflammation in the presence or absence of PIMs. Therefore, I used 
gadolinium chloride (GC) to deplete PIMs. GC has previously been used to remove PIMs 
in vivo in sheep, cattle and horses and alveolar macrophages in mice and rat (Staub, 
1994), (Singh et al., 2004), (Parbhakar et al., 2004). GC induces apoptosis in PIMs to 
significantly reduce their numbers within 48 hours of the treatment (Singh et al., 2004). I 
found that GC reduced PIM numbers in BDL rats at 48 hours of the treatment to near 
significance levels (p=0.06). Histological evaluation of lung sections suggested that 
PIMs in GC-treated rats may be undergoing apoptosis. However, I did not confirm this 
observation with additional methods such as TUNEL or detailed electron microscopy. It 
is possible that PIM function may be more compromised than suggested by histological 
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numerical counts of ED-1 cells. Decline in ED-1 positive PIMs in lung sections directly 
quantifies the dead cells that have been physically removed from the capillaries. 
Although GC can block Kupffer cells as early as 6 hours of treatment (Kim and Choi, 
1997), (Brown et al., 1997), it takes much longer for the induction of apoptosis and 
removal of apoptotic cells. Dysfunctional or dead PIMs in GC-treated rats that are still to 
be removed from the capillaries may be recognized by ED-1 antibody. Therefore, GC 
may compromise PIM function to a higher degree than is captured by ED-1 staining of 
lung sections.   
 
There were no effect of GC treatment on the lung expression of IL-1β and TNF-α. 
However, lungs of rats treated with GC compared to BDL rats had higher concentrations 
of TGF-β and IL-10 mRNA but not the protein. It is possible that the time point 
examined in my study may not be sufficient for translation of mRNA into the protein,  
However, if increased levels of mRNA are translated into the protein forms of TGF-β and 
IL-10, the data would fit with previously demonstrated increased expression of TGF- β in 
tissues that contain apoptotic cells (Lucas et al., 2003), (Huynh et al., 2002). IL-10 is also 
an anti-inflammatory cytokine and its increased expression may be related to GC-induced 
apoptosis in lungs. Furthermore, BDL rats treated with GC continued to express higher 
levels of MCP-1 mRNA and protein. Based on the established roles of MCP-1 in 
recruitment of monocytes/macrophages, higher expression of MCP-1 in GC-treated BDL 
or BDL rats would suggest ongoing recruitment of monocytes/macrophages. Increased 
MCP-1 expression may also be necessary to promote migration of 
monocytes/macrophages to remove apoptotic cells in GC-treated rats. However, these 
speculations need to be confirmed with additional studies to show recruitment of fresh 
monocytes/macrophages into the lungs. These studies may include experiments where 
MCP-1 is blocked with antibodies or the use of MCP-1 knockout rats. 
 
I noticed discordance in the expression of TGF-β and IL-10 mRNA and proteins. 
Although I do not know the precise reasons but it could be due the following reasons. 
First, the RT-PCR followed by densitometry is semi-quantitative at best while the ELISA 
is a quantitative method. Second, there could be an interference in the translation of 
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mRNA into the protein product in these tissues. Lastly, because protein is the active and 
functional product of the gene, I decided to rely more on the protein data than the mRNA. 
 
These data show that BDL causes substantial recruitment of ED-1 positive PIMs. 
However, recruitment of PIMs does not induce expression of inflammatory cytokines in 
the rats. Because GC effectively depletes PIMs, this provides us with a reliable model to 
study lung inflammation with or without PIMs to delineate their contributions.   
 
7.3. Recruited PIMs in lung inflammation 
I examined the role of recruited PIMs in LPS-induced lung inflammation. The data show 
that LPS treatment of BDL rats induced more severe inflammation and mortality 
compared to that of LPS-treated normal rats. It is interesting to note that BDL rats 
suffered 100% mortality within 3 hours of the LPS administration while the normal LPS-
challenged rats were euthanized at 6 hours after the treatment. The mortality data in the 
current study are similar to those reported by Chang and O’Hara in their experiments on 
BDL rats challenged with LPS (Chang and Ohara, 1994). However, these authors did not 
examine the mechanisms of increased mortality in BDL rats challenged with LPS. To 
address this issue, I evaluated the expression of IL-1β and TNF-α which are central to 
LPS-induced lung inflammation and mortality. Although densitometry did not show 
increase in mRNA expression but ELISA detected increased IL-1β and TNF-α 
concentrations in lungs from LPS-treated BDL rats compared to the normal LPS-treated 
rats. Both of these cytokines are central to LPS-induced inflammation associated with 
mortality and morbidity (Zanotti et al., 2002), (Strieter et al., 1993), (Debets et al., 1989), 
(Dinarello et al., 1989), (Creasey et al., 1991), (Shapira et al., 1996). Specifically, IL-1β 
is central to endotoxin-induced cardiopulmonary shock (Dinarello et al., 1989), (Fischer 
et al., 1991). Immuno-electron microscopy localized both the cytokines in PIMs of LPS-
challenged BDL rats. These data are similar to the expression of IL-1β and TNF-α in 
PIMs of LPS-challenged horses; a species which is highly susceptible to endotoxin-
induced lung inflammation and mortality (Parbhakar et al., 2005). Therefore, PIMs may 
orchestrate lung inflammation and mortality by producing proinflammatory cytokines to 
induce expression of adhesion molecules and activate other vascular cells.   
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The increased LPS-induced mortality in BDL rats compared to LPS-challenged normal 
rats suggests a causal link with recruited PIMs. However, to clearly establish the role of 
recruited PIMs, I investigated LPS-induced lung inflammation in BDL rats treated with 
GC. The data showed effectiveness of GC in removal of PIMs in BDL rats.  Therefore, I 
treated rats with GC 6 hours or 48 hours before an intravenous challenge with LPS. The 
reason for selecting these two post-GC time points was based on previous evidence that 
GC can quickly deactivate macrophages within 6 hours before actually causing apoptosis 
in them by 24-48 hours (Kim and Choi, 1997), (Brown et al., 1997). Therefore, I thought 
to examine the two time points that capture the impact of functional deactivation as well 
as physical death of PIMs on LPS-induced lung inflammation and mortality.  
 
I noticed striking reduction in mortality rates in GC and LPS treated rats. Rats that were 
treated with GC 6 hours before the LPS treatment showed 80% survival rates. The 
survival increased to 100% if the rats were given LPS at 48 hours post-GC treatment. 
This is in contrast to 100% mortality in BDL rats within 3 hours of LPS challenge. I 
conclude that both physiological deactivation as well as physical elimination of PIMs has 
beneficial effects on lung inflammation and host survival. 
 
I found a significant reduction in the mRNA expression as well as protein concentration 
of MCP-1 in rats treated with GC at 6 hours and 48 hours before LPS administration. 
Because monocytes and macrophages produce as well as regulate production of MCP-1, 
the inactivation or depletion of PIMs may be responsible for reduced levels of MCP-1 
mRNA and protein in lungs of LPS-challenged BDL rats. BDL rats treated with GC 
before LPS challenge showed a decline in numbers of ED-1 positive cells compared to 
BDL rats treated with LPS. Because MCP-1 is a critical regulator of monocyte 
recruitment (Maus et al., 2001) , its reduced expression in lungs of PIM-depleted rats 
may suppress further recruitment of ED-1 positive cells and result in less severe lung 
inflammation.  
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Although GC treatment of BDL rats at 6 hours prior to LPS challenge resulted in 
increased survival, it did not reduce mRNA expression and protein concentrations of IL-
1β and TNF-α compared to LPS-treated BDL rats. One of the reasons could be that GC 
causes only partial inactivation and not death in macrophages at this early time point after 
the treatment. This would result in secretion of preformed or newly formed cytokines by 
the PIMs. Another possibility could be that GC interfered with release of cytokines and 
chemokines from recruited PIMs as well as other lung cells by blocking their chloride 
channels. This would create a scenario where lung homogenates would contain higher 
levels of cytokines but there will not be increased expression of adhesion molecules 
followed by recruitment of neutrophils resulting in the survival of LPS-challenged 
animals. Of more interest are the results on the expression of IL-1β and TNF-α in BDL 
rats treated with LPS at 48 hours post-GC treatment. Lungs of these rats showed reduced 
expression of both the cytokines compared to BDL+LPS rats. Immuno-electron 
microscopy confirmed IL-1β and TNF-α in PIMs in LPS-challenged BDL rats. Therefore, 
reduced levels of IL-1β and TNF-α protein may be a direct in addition to indirect result of 
GC-mediated PIM depletion. Because PIMs produce pro-inflammatory cytokines, their 
removal prior to LPS challenge will eliminate a key regulator of cell activation and lung 
inflammation to result increased host survival.   
 
Because inflammation is an outcome of interplay between molecules that promote or 
suppress inflammation, I also focused on the expression of TGF-β and IL-10. TGF-β 
protein concentrations were higher in all the groups including the BDL groups compared 
to the LPS-challenged control rats. As discussed earlier, TGF-β is an anti-inflammatory 
cytokine and its expression increases in tissues undergoing apoptosis. Therefore, it is an 
expected result where GC has induced apoptosis in PIMs, which in turn contributes to 
increased expression of TGF-β. Furthermore, LPS treatment of rats has been shown to 
suppress expression of TGF-β. However, mRNA expression and protein concentrations 
of IL-10 in both 6 hour and 48 hour GC groups were lower as compared to LPS treated 
BDL group. IL-10 is produced by activated mononuclear cells on exposure to LPS, which 
in turn deactivates macrophages (Bogdan et al., 1991) and inhibits pro-inflammatory 
cytokine production by the activated macrophages (Strassmann et al., 1994), (Platzer et 
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al., 1995). This suggests higher mRNA expression and protein concentrations of IL-10 in 
our LPS treated BDL rats. It has also been shown that IL-10 concentration increases with 
the number of recruited mononuclear phagocytes with in first 3 days after LPS challenge 
and then decreases to undetectable levels (Salez et al., 2001), (Chabot et al., 2003). 
Therefore, my data show GC treatments resulted in lower mRNA expression and protein 
concentration of IL-10. The effect on IL-10 expression could be due to direct inactivation 
and depletion of PIMs. 
 
This study has some weaknesses. First and foremost it is critical to examine the 
recruitment of neutrophils in rat lungs in various groups. Although both PIM inactivation 
or depletion resulted in increased survival of BDL rats, there may be differences in the 
mechanisms between these two instances. For example PIM inactivation caused 
increased survival without reducing the expression of cytokines. Because activated 
neutrophils cause tissue damage and death, it will be interesting to see if there were 
quantitative differences in the migration of neutrophils in these two scenarios. I believe 
that it is important to undertake a detailed examination of morphology and cytokine 
expression in the liver of these animals. Although BDL stimulates recruitment of PIMs, it 
will be interesting to see if such phenomenon also occurs in the spleen as well. 
 
The results presented in this thesis show that PIMs are recruited in a rat model of biliary 
cirrhosis and that recruited PIMs do not induce lung inflammation. However, upon an 
LPS challenge these PIMs become inflammatory and induce significant lung 
inflammation and mortality. The direct role of PIMs in inflammation and mortality in the 
rats is established by inhibition of these events upon deactivation or death of PIMs. These 
data are novel and have direct bearing on our understanding of PIMs’ roles in HPS in 
humans and lung inflammation in domestic animals. Furthermore, the data underscore 
PIMs as potential targets for therapeutic interventions. These studies also provide a rat 
model to study PIMs contributions to lung inflammation in domestic animals at a much 
reduced rates. 
.   
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8. CONCLUSIONS 
 
1. Bile duct ligation induces recruitment of PIMs in rats without activation of lung 
inflammation. 
 
2. Recruited PIMs increases sensitivity to LPS induced lung inflammation and result in 
substantial mortality. 
 
3. Depletion or inactivation of PIMs protects against the severity of LPS induced lung 
inflammation and mortality. 
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9. FUTURE RESEARCH 
 
First, it is important to further characterize the expression of various inflammatory genes 
in lungs of BDL rats as well as directly in recruited PIMs. Second, there is a need to 
develop methods to cause more rapid and effective depletion or inactivation of PIMs. 
Third, we need better delivery methods to target depleting chemicals specifically to 
PIMs. Fourth, I think it will be useful to examine if PIMs are present in lung autopsy or 
biopsy materials from human patients suffering from various systemic or lung diseases.  
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